B
74.07
1.36 (1.88%)
| Previous Close | 72.70 |
| Open | 74.02 |
| Volume | 1,599,076 |
| Avg. Volume (3M) | 2,306,182 |
| Market Cap | 14,272,978,944 |
| Price / Sales | 39.92 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2026 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 1.5 |
| Insider Activity | -3.5 |
| Price Volatility | -4.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.10 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (Cantor Fitzgerald, 48.52%) | Buy |
| Median | 90.00 (21.52%) | |
| Low | 71.00 (Raymond James, -4.14%) | Buy |
| Average | 89.55 (20.91%) | |
| Total | 11 Buy | |
| Avg. Price @ Call | 65.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 15 Dec 2025 | 86.00 (16.11%) | Buy | 74.51 |
| Bernstein | 11 Dec 2025 | 94.00 (26.92%) | Buy | 74.07 |
| Wells Fargo | 11 Nov 2025 | 84.00 (13.41%) | Buy | 66.58 |
| JP Morgan | 07 Nov 2025 | 77.00 (3.96%) | Buy | 61.80 |
| HC Wainwright & Co. | 03 Nov 2025 | 90.00 (21.51%) | Buy | 61.98 |
| 29 Oct 2025 | 90.00 (21.51%) | Buy | 66.62 | |
| Goldman Sachs | 31 Oct 2025 | 100.00 (35.02%) | Buy | 62.64 |
| Cantor Fitzgerald | 30 Oct 2025 | 110.00 (48.52%) | Buy | 63.37 |
| Piper Sandler | 30 Oct 2025 | 98.00 (32.32%) | Buy | 63.37 |
| Raymond James | 30 Oct 2025 | 71.00 (-4.14%) | Buy | 63.37 |
| 21 Oct 2025 | 59.00 (-20.34%) | Buy | 54.36 | |
| TD Cowen | 30 Oct 2025 | 95.00 (28.27%) | Buy | 63.37 |
| Truist Securities | 30 Oct 2025 | 80.00 (8.01%) | Buy | 63.37 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| APULI MARICEL | - | 75.15 | -2,003 | -150,525 |
| KUMAR NEIL | - | 74.83 | -60,975 | -4,563,064 |
| TRIMARCHI THOMAS | - | 75.15 | -13,826 | -1,039,024 |
| Aggregate Net Quantity | -76,804 | |||
| Aggregate Net Value ($) | -5,752,614 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 74.99 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KUMAR NEIL | Officer | 15 Dec 2025 | Automatic sell (-) | 30,011 | 74.51 | 2,236,120 |
| APULI MARICEL | Officer | 12 Dec 2025 | Disposed (-) | 2,003 | 75.15 | 150,525 |
| TRIMARCHI THOMAS | Officer | 12 Dec 2025 | Disposed (-) | 13,826 | 75.15 | 1,039,024 |
| KUMAR NEIL | Officer | 12 Dec 2025 | Disposed (-) | 30,964 | 75.15 | 2,326,945 |
| KUMAR NEIL | Officer | 12 Dec 2025 | Option execute | 60,975 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |